One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Abbott Laboratories (ABT): score, valuation & FAQ
Abbott Laboratories (ABT) is a Medical Devices company that scores 59.3 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are FCF (B+). On valuation, ABT sits about 5% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 6% annual free-cash-flow growth over the next decade.
Is ABT a good stock to buy?
Bull Rankings scores ABT 59.3 out of 100 on its quality-growth model, which is a middling reading. That is driven by FCF (B+). A score is a quantitative screen of Abbott Laboratories's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ABT score 59.3 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ABT earns its highest marks on FCF (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is ABT overvalued or undervalued?
Based on $100.57, ABT sits about 5% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 6% annual free-cash-flow growth over the next decade. It trades at a 32.2x× P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ABT?
Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.